| Novel targets for development of drugs for treating schizophrenia: focus on glycine, D-serine and nitric oxide | Jaime HALLAK, Marnie MACKAY, Glen BAKER, Serdar DURSUN, Kamaldeep DHAMI, Joao Paulo Maia-de OLIVEIRA, Kathryn TODD | 129–137 |
| Remisyondaki şizofreni hastalarında ve birinci dere- ce yakınlarında kişilik özellikleri: Dopaminerjik ve glutamaterjik gen polimorfizmi çalışması | Vesile ALTINYAZAR, Azad GUNDERİCİ | 138–148 |
| Risk management in tianeptine abuse in Turkey: a national experience | Guven ARTİRAN, Saim KERMAN, Gamze OZBİLEN, Yelda KASAP, Oguzhan KOYUNCU, Demet AYDINKARAHALİLOGLU, Osman YILDIRIM, Nedim DURMUS | 149–154 |
| Descriptive features of depressive disorder patients with who have committed suicide by drug overdose | Omer DEMİREL, Hamdi TUTKUN, H. Murat EMUL, Gurol BERBER, Muhammed Nabi KANTARCI, Mustafa BALKAY, Eyup KANDEMİR | 155–161 |
| The effect of methylphenidate on executive functions in children with Attention-Deficit Hyperactivity Disorder | Emine FETTAHOGLU CIGIL, Esin OZATALAY, Alper YILMAZ, Cem GOKCEN | 162–170 |
| Relationships between use of long acting antipsychotics and sociodemographic and clinical characteristics of patients with schizophrenia | Murat BEYAZYUZ, Cuneyt UNSAL, Yakup ALBAYRAK | 171–179 |
| Idiopathic thrombocytopenia side-effect of lithium in a patient with schizophrenia | Branislav O SAKIC, Josip Dj DADASOVIC | 180–182 |
| Fluoxetine induced hypomanic shift in a bulimic patient: Case report | Atila EROL, Mustafa OZTEN | 183–185 |
| Metoclopramide induced akathisia: A case report | Aslihan IBİLOGLU OKAN | 186–189 |
| Vitamin E treatment for olanzapine induced tardive dyskinesia in an adolescent with Bipolar Disorder | Rabia BİLİCİ, Ali Evren TUFAN, Irem YALUG | 190–192 |
| Glycogen synthase kinase-3: a new therapeutic target in mood disorders | Salih GUMRU, Feyza ARİCİOGLU | 193–198 |